SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Micromet Inc (MITI)
MITI 0.120+33.3%12:18 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Arthur Radley4/21/2010 9:57:10 AM
  Read Replies (1) of 196
 
Micromet (MITI) Achieves Milestone with Bayer Schering Regarding BiTE Antibody Solid Tumor Treatment
8:58 am ET 04/21/2010 - StreetInsider
Micromet, Inc. (Nasdaq: MITI) announced today that it has achieved a milestone under its collaboration agreement with Bayer Schering Pharma AG. The milestone was triggered by Micromet's achievement of pre-clinical proof of concept for a BiTE antibody for the treatment of solid tumors.

"We have made important progress in advancing the development of this program since signing the collaboration agreement in January 2009," said Jens Hennecke, Ph.D., Micromet's Senior Vice President, Business Development. "We look forward to continuing our productive collaboration with Bayer Schering Pharma."

Under the terms of the collaboration agreement Micromet is primarily responsible for the pre-clinical development of the BiTE antibody, and will collaborate with Bayer through the completion of phase 1 clinical trials. Bayer is responsible for product development beginning in phase 2, and for all manufacturing and commercialization activities. Micromet is entitled to receive progress dependent milestone payments of up to 285 million Euros and up to double digit royalties on net sales. In addition, Micromet will be reimbursed for its R&D expenses
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News